Boehringer Ingelheim and Sosei Heptares Collaborate for the Development of Therapies to Address Schizophrenia Symptoms
Shots:
- Boehringer Ingelheim & Sosei have signed a global collaboration & exclusive option-to-license agreement for the development & commercialization of the latter’s GPR52 agonists portfolio incl. HTL0048149 to address schizophrenia symptoms
- As per the agreement, BI gains an exclusive licensing option for Sosei’s GPR52 agonists portfolio after completing the P-I, P-Ib & P-II clinical evaluations of HTL0048149. Sosei retains trial control & sponsorship until the option exercise, expected in 2025
- Sosei obtains ~$27.35M upfront upon signing, ~$65.64M as option exercise payment & a total of ~$733.07M on achieving development, regulatory & commercialization milestones along with customary sales-based tiered royalties
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- Sosei Heptares Initiates to Reclaim Ownership GSK4381406 from GSK
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
